The current standard treatment for patients with MIBC involves radical cystectomy, which is invasive and severely affects the patients' quality of life.[6] For advanced BLCA, the first‐line treatment remains cisplatin‐based combination chemotherapy, which often leads to severe side effects.[7] In recent years, the Food and Drug Administration has approved several immune checkpoint inhibitors that target programmed cell death protein 1 and programmed cell death ligand 1 for the treatment of advanced or metastatic BLCA. This evidence concerns the gene PDCD1 and bladder transitional cell carcinoma.